Full Breakdown
Bayer’s $7.25 Billion Roundup Settlement Faces Missouri Court Decision
By Drooid · · How we work
Core Event – Missouri Hearing on Proposed Settlement
On September 14, 2026, a Missouri state court will hear arguments from Bayer AG’s Monsanto unit seeking approval of a $7.25 billion settlement intended to resolve tens of thousands of U.S. lawsuits alleging that the Roundup herbicide causes cancer. Judge Timothy Boyer is presiding over the hearing, which will consider objections from plaintiffs’ attorneys and arguments from supporters of the deal. The court’s ruling is not expected to be issued immediately.
Background & Context
Bayer acquired Monsanto in 2018, inheriting a growing body of litigation over Roundup, whose active ingredient is glyphosate. By 2026 the company faces roughly 65,000 claims in state and federal courts alleging that exposure to Roundup led to non-Hodgkin lymphoma. A 2020 settlement of about $10 billion resolved many existing cases but left future claims unresolved. A June U.S. Supreme Court decision limited plaintiffs’ ability to argue that Roundup’s label should have warned of cancer risks, prompting renewed settlement negotiations.
Data & Statistics
- Claims: ~65,000 pending lawsuits.
- Proposed payout range: $10,000 to $165,000 per claimant, based on cancer severity, age at diagnosis, and exposure setting (home or work).
- Exposure estimate: Studies cited by opponents suggest ?80 % of Americans have been exposed to glyphosate.
- Previous settlements: $10 billion in 2020; a failed $1.25 billion attempt to cover future claims.
Official Statements & Responses
Bayer continues to deny that glyphosate causes cancer, citing decades of studies indicating safety.
Criticism & Opposition
Attorney T. He highlighted the $7.25 billion** figure as “just not enough.”
Why It Matters – Market and Legal Impact
The litigation over Roundup has been a persistent overhang on Bayer’s share price since the 2018 acquisition. Investor sentiment rose on September 14, 2026 as the stock traded in the mid-€49 range, reflecting optimism that a court approval could remove a major liability. Analysts maintain “Buy” ratings with price targets ranging from €58 to €70, indicating perceived upside if the settlement clears the legal cloud. Conversely, failure to secure approval could prolong uncertainty and increase future costs.
Conflicting Reports & Gaps
Sources differ on the hearing date: Reuters reports the hearing is set for September 14, 2026, while ad-hoc-news outlets state the “pivotal test” occurs on September 11, 2026. Both accounts agree the case will be heard by Judge Boyer, but the exact schedule remains unclear.
Verbatim Quotes
- “Even though $7.25 billion looks like a lot of money, it's just not enough,” — T. Roe Frazer, an attorney opposing the settlement
What’s Next
Judge Boyer will review the settlement framework and objections, with a decision expected after the hearing. The U.S. Environmental Protection Agency plans to complete an updated human-health risk assessment for glyphosate by late 2026, which could influence future regulatory actions but is separate from the court’s immediate determination.